Sangamo downgraded to Equal Weight from Overweight at Barclays

Barclays downgraded Sangamo (SGMO) to Equal Weight from Overweight with a price target of $1, down from $5. The company’s Q3 report highlighted the FDA’s reaffirmation of an accelerated approval path using eGFR slope as the endpoint and its cash runway has been extended into Q1 of 2026, the analyst tells investors in a research note. Barclays steps to the sidelines pending further clarity on a Fabry deal.